15:20 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Pancreatitis Mouse studies suggest PIEZO1 inhibition could help treat pancreatitis. In a mouse model of pressure-induced acute pancreatitis, pancreatic acinar cell-specific knockout of PIEZO1 or the PIEZO1 inhibitor AT-300 decreased histological disease scores and...
20:17 , Mar 24, 2017 |  BC Week In Review  |  Clinical News

HT-100 regulatory update

FDA granted Akashi clearance to resume clinical development of Duchenne muscular dystrophy (DMD) candidate HT-100. The company said it plans to start a new Phase IIa trial “as quickly as possible.” In January 2016, Akashi...
22:31 , Mar 22, 2017 |  BC Extra  |  Clinical News

Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100 . The company said it intends to start a new Phase IIa trial “as...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa halted

Akashi said that a patient treated with HT-100 in the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD has died. In late January, Akashi suspended dosing and...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

Halofuginone: Phase Ib/IIa suspended enrollment

Akashi suspended dosing and enrollment in all cohorts of the open-label, U.S. Phase Ib/IIa HALO trial in boys and young men with ambulatory or non-ambulatory DMD after 1 patient receiving once-daily 60 ug/kg HT-100, the...
01:47 , Jan 27, 2016 |  BC Extra  |  Clinical News

Akashi halts DMD program

Akashi Therapeutics Inc. (Cambridge, Mass.) said it suspended dosing and enrollment of all clinical studies of HT-100 to treat Duchenne muscular dystrophy after a patient experienced undisclosed "serious, life-threatening health issues." The patient had been...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Akashi Therapeutics, Gruenenthal deal

The companies partnered exclusively to develop and commercialize Akashi’s HT-100 . Gruenenthal will be responsible for development following Phase II testing and also will develop Akashi’s U.S. commercial infrastructure. Akashi granted Gruenenthal rights to commercialize...
02:22 , Jan 9, 2016 |  BC Extra  |  Company News

Patient-funded Akashi partners DMD compound

Akashi Therapeutics Inc. (Cambridge, Mass.) and Gruenenthal Group (Aachen, Germany) partnered to develop Akashi's HT-100 for Duchenne muscular dystrophy (DMD). The compound, an oral delayed-release formulation of the collagen type I ( COL1 ) inhibitor...
07:00 , Oct 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Eukaryotic translation initiation factor 2 α kinase 4 (EIF2AK4; GCN2)

Autoimmune disease INDICATION: Lupus Cell culture and mouse studies suggest promoting EIF2AK4 activity could help treat lupus. In a mouse model of lupus, macrophage-specific knockout of EIF2AK4 increased numbers of spleen cells, spleen levels of...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Halofuginone: Additional Phase Ib/IIa data

Data from 10 boys and young men with ambulatory or non-ambulatory DMD in the open-label, U.S. Phase Ib/IIa HALO-DMD-01/02 trial showed that once-daily HT-100 increased mean total muscle strength, as measured by quantitative muscle testing...